End-Stage Renal Disease Perspective

 
 
  • The Kidney and COVID-19: What We Know so Far   Nephrologists Matthew Sparks and Samira Farouk, of the Freely Filtered podcast, discuss the kidney effects of COVID-19 -- what is and isn't clear in patients with and without preexisting kidney disease.
  • Could a VA Directive Overhaul Kidney Care? Directive 1053 may have gotten lost in the pandemic news, but it could have widespread implications for the management of CKD by nephrologists and primary care. Tejas Desai, MD, takes a closer look.
  • ERA-EDTA 2020 Read clinically focused news coverage of key developments from ERA-EDTA 2020
  • NKF 2020 Read clinically focused news coverage of key developments from NKF 2020
  • ISN 2020 Read clinically focused news coverage of key developments from ISN 2020
  • Cardios, Nephros, PCPs -- We're All Diabetologists Now Newer diabetes medications are proving effective in reducing CV events, hospitalizations for heart failure, and progression to dialysis. So where do these drugs belong?
  • ACIP 2020 Child/Teen Immunization Schedule: The Highlights A quick tour of key changes in the 2020 ACIP child/adolescent immunization schedule.
  • Dialysis Industry Mergers: Profits Rise as Outcomes Worsen An economic analysis of the dialysis industry shows how the usual benefits of mergers are negated in the healthcare industry by imprudent financial incentives and lack of true competitive market forces.
  • Palliative Care in End-Stage Renal Disease In this case, a social worker must respond to a patient who expresses that she would like to discontinue dialysis and knows that doing so means she will die soon.
  • Trump Should Get Kudos for Looking at Kidney Dialysis, Transplant   Dr Art Caplan discusses President Trump's ideas regarding re-examination of dialysis and kidney transplant in the US, and the need to improve access to immunosuppressive drugs post-transplant.
  • Study Underscores Need for Long-term Follow-up After AKI Focusing on eGFR alone may underestimate long-term kidney damage in some patients with AKI, concludes Dr Nisha Bansal in reviewing a new study.
  • Advancing American Kidney Health: The Ultimate RCT? President Trump's Executive Order puts nephrology center stage. Tejas Desai, MD, reviews what the initiative entails for kidney disease clinicians and what details are yet to come.
  • How Do the Renal Data From CREDENCE and CARMELINA Compare?   Meg Jardine and Christoph Wanner, investigators from the CREDENCE and CARMELINA trials, respectively, discuss the implications for SGLT2 inhibitor and DPP-4 inhibitor use in patients with kidney disease.
  • Just Say No to the ICD in Patients With Kidney Disease Little evidence supports the use of ICDs in patients with kidney disease. A bold new study in patients on dialysis suggests that the devices should be avoided. John Mandrola, MD, weighs in.
  • ERA-EDTA 2019 Read clinically focused news coverage of key developments from ERA-EDTA 2019
  • Discarded No More: HCV-Infected Organs Advance Transplantation Direct-acting antiviral therapy has made the use of HCV-infected organs a reality. Here is an inside look at one liver transplant program as they deliberate this option for their patients.
  • Urinary Oxalate and CKD Progression: Is There an Association? Dr Bansal reviews a study that examines whether higher urinary oxalate excretion predisposes patients to kidney disease progression.
  • No Firm Answers for Kidneys From LIRICO and VALID Studies Is dual RAS blockade in patients with diabetes with kidney disease beneficial? Dr Desai reviews two studies designed to answer that question.
  • CREDENCE Takes SGLT2 Inhibitors 'to the Next Level' What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.
  • Is CREDENCE a Game Changer for Diabetic Nephropathy? The medical community is marveling at the results of the CREDENCE trial. But can one study really change clinical practice? Perry Wilson shares his thoughts.